Head-to-head evidence
albuterol HFA (Armstrong's) vs albuterol (Ventolin)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol HFA (Armstrong's)
Marketed by Amphastar Pharmaceuticals, Inc.
NCT00635505 · Phase 3 · terminated
This is a randomized, quadruple-blind, placebo- and active-controlled study with an adequate sample size measuring lung function directly, but no results have been posted yet, so the outcome is unknown.
albuterol (Ventolin)
Developed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT06676319 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol HFA (Armstrong's)'s landscape · albuterol (Ventolin)'s landscape